Safety And Tolerability Of Multiple Dose Lersivirine For 21 Days In Healthy Subjects

Summary

Randomized, open-label, parallel group study in a group of 75 healthy subjects, to evaluate the safety and toleration of 2 different doses of lersivirine administered either fed or fasted (proposed Phase 3 formulation) given over 21 days, compared to lersivirine 500 mg QD (Phase 2b formulation). The pharmacokinetics of lersivirine in each group will also be evaluated.

Timeline

Start

2010-10

Primary completion

2011-05

Completion

2011-05

Drugs

Indications

No indication recorded.